美年健康(002044.SZ)前2月營收同比增長17%
格隆匯3月10日丨美年健康(002044.SZ)公佈,2022年開年以來,公司經營延續去年第四季度的趨勢繼續穩健提升,深化落實創新工作。在常規業務持續精細化運營和數字化轉型的基礎上,持續推進創新項目的引進和開展,同時全面啟動人工智能在心臟、呼吸、消化道、腦健康,眼底等專科領域的應用,並積極提升膠囊胃鏡、基因檢測等優勢項目的推廣。促進個檢項目線上線下銷售並積極拓展優質企業客户,2022年1至2月,公司營業收入同比增長17%,其中到檢人數同比增長5%,客單價同比增長12%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.